Prof. PeptideProf. Peptide

Follistatin

Performance & EnergyResearch-Grade

Last reviewed: September 20, 2026

Quick Facts

What it is
A myostatin-inhibiting protein (FS-344, or Follistatin-344) that removes the body's natural brake on muscle growth — much of the strongest muscle-growth evidence comes from gene therapy and animal models rather than the injectable peptide.
How it's taken
Subcutaneous injection for the research peptide; intramuscular for gene-therapy delivery
Half-life
~90 minutes (injectable peptide)
Typical research dose
100–200 mcg per day, in 10–30 day cycles with 3–4 weeks off
Research status
Not FDA-approved — research use only.
On this page
  1. 1.Where to source Follistatin
  2. 2.What is Follistatin?
  3. 3.How does Follistatin work?
  4. 4.What is Follistatin used for?
  5. 5.How long does Follistatin take to work?
  6. 6.How is Follistatin dosed?
  7. 7.How is Follistatin administered?
  8. 8.What does Follistatin stack well with?
  9. 9.What are the side effects of Follistatin?
  10. 10.Does Follistatin interact with other drugs?
  11. 11.How should Follistatin be stored?
  12. 12.What are the limitations of Follistatin research?
  13. 13.Follistatin FAQ
  14. 14.References
  15. 15.Published Studies

Where to source Follistatin

Follistatin is not FDA-approved and is sold only as a research-grade peptide. It is one of the most expensive research peptides per milligram due to recombinant production complexity, and counterfeit or underdosed product is common — verify Certificate of Analysis before purchase. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes.

Royal Peptides10% off

cGMP/ISO labs · batch COAs

Shop Royal Peptides
Compare prices across 3 vendors

See all 88 verified vendors

What is Follistatin?

Follistatin is a naturally occurring single-chain glycoprotein that functions as a potent inhibitor of the myostatin pathway. Myostatin is the body's primary negative regulator of skeletal muscle growth — it places a ceiling on how much muscle a person can build. By binding and neutralizing myostatin, follistatin allows muscle growth beyond normal genetic limits. The injectable research form is FS-344 (Follistatin-344), a 344-amino-acid precursor protein that the body cleaves into two functional isoforms: FS-315 (circulating, muscle-targeting) and FS-288 (tissue-bound, gonad-concentrated). Strong gene therapy data exists in primates (15% muscle growth persisting 15+ months) and Becker muscular dystrophy patients; injectable peptide human data is minimal. Often stacked with IGF-1 LR3 or the GH Stack for compounded anabolic effect. New to peptide research? Start with the basics

Reported benefits:

  • Inhibits myostatin, removing the body's primary muscle growth ceiling
  • Enables both hypertrophy (bigger fibers) and hyperplasia (more fibers)
  • Inhibits activin A, providing dual-action anti-catabolic effect
  • Promotes satellite cell proliferation for enhanced muscle regeneration
  • Reduces fat deposition (myostatin deficiency lowers adipogenesis)
  • Strong gene therapy efficacy data in primates and humans

Common research dose: No human trial has established an injectable-peptide dose; reported research-community practice is 100–200 mcg per day administered subcutaneously, in 10–30 day cycles followed by 3–4 weeks off. Daily dosing is required because the injectable peptide has a ~90-minute half-life. A published case series documents central serous chorioretinopathy (a retinal fluid condition affecting vision) in 11 bodybuilders who injected complete 1 mg vials — several times the community-reported figure.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does Follistatin work?

Follistatin works by binding myostatin — the body's natural brake on muscle growth — and preventing it from signaling muscle cells to stop growing. It also binds activin A and promotes satellite cell proliferation, giving it three distinct mechanisms that together produce muscle growth beyond normal genetic limits. The injectable peptide form (FS-344) is cleaved in vivo into two isoforms with different tissue affinities, which is what gives follistatin both its muscle effect and its reproductive-hormone side-effect profile.

  1. Myostatin Neutralization [1]. Follistatin binds myostatin with extremely high affinity (Kd ~5–10 pM), forming a complex that prevents myostatin from binding to its receptor (ActRIIB) on muscle cells. With the myostatin signal blocked, muscle protein synthesis tilts toward net accretion.
  2. Activin A Binding [2]. Follistatin also binds activin A, which has additional growth-suppressive effects beyond myostatin. The dual mechanism is part of why follistatin produces greater muscle effects than myostatin-only inhibitors.
  3. Isoform Cleavage [1][3]. Injected FS-344 is cleaved in vivo into two functional isoforms: FS-315 (the circulating form, lower affinity for activin) and FS-288 (tissue-bound, higher affinity for activin, concentrates in gonads). FS-315 is responsible for systemic muscle effects; FS-288 carries reproductive-tissue activity.
  4. Satellite Cell Proliferation [4]. Follistatin promotes satellite cell (muscle stem cell) proliferation, supporting muscle regeneration and enabling hyperplasia (new muscle fiber formation) in addition to hypertrophy.
  5. ActRIIB Pathway Modulation [3]. By blocking myostatin's binding to ActRIIB, follistatin prevents the downstream cascade that activates SMAD2/3 transcription factors and ultimately the gene expression patterns that limit muscle growth.

What is Follistatin used for?

Follistatin's strongest clinical evidence comes from gene therapy approaches in muscular dystrophy and primate models, not injectable peptide use. The injectable form (FS-344) has minimal published human data — most use sits in research and bodybuilding communities. The research areas below cover the published evidence base across gene therapy, animal models, and the limited injectable peptide data that exists.

  1. Muscular Dystrophy Gene Therapy [3]. The strongest follistatin clinical evidence comes from AAV1-FS344 gene therapy trials in Becker muscular dystrophy patients (Mendell et al., Mol Ther 2015). Patients showed improved ambulation and increased muscle strength after a single intramuscular injection of the gene therapy vector.
  2. Primate Muscle Growth [5]. In cynomolgus macaque monkeys, AAV1-FS344 gene therapy injected into the quadriceps produced 15% circumference increase at 8 weeks, with effects persisting 15+ months from a single dose. The study demonstrated both efficacy and long-term safety.
  3. Mighty Mice Studies. Mice with FS-344 overexpression showed up to 2x normal muscle mass. Mice with both myostatin deletion AND FS-344 overexpression showed nearly 4x normal muscle mass, suggesting follistatin works through additional pathways beyond pure myostatin inhibition.
  4. Sarcopenia and Aging Models. Follistatin is studied in age-related muscle wasting models. Theoretical applications in elderly populations are promising but unvalidated for injectable peptide use.
  5. Injectable Peptide Human Data [6]. Minimal. Most peer-reviewed follistatin human data comes from gene therapy approaches. The injectable peptide form (FS-344) has a ~90-minute half-life and limited published efficacy data, with most use coming from research and bodybuilding communities.

How long does Follistatin take to work?

Follistatin effects develop over the cycle, with strength and muscle fullness sometimes reported within 2 weeks of consistent daily dosing — no trial or label has been identified establishing this timeframe. Injectable peptide effects are likely more modest than gene therapy results due to the short half-life and rapid clearance. Pairing with consistent resistance training and adequate protein is essential — without the training stimulus, follistatin removes a ceiling that isn't being pushed against.

Most users report noticeable strength and muscle fullness within the first 2 weeks of consistent dosing. Gene therapy studies (which produce sustained expression) showed measurable changes by week 8. Injectable peptide effects are likely much more modest than gene therapy results due to the short half-life and rapid clearance. Most reliable effects come when paired with consistent resistance training, adequate calories, and sufficient protein intake — without the training stimulus, follistatin's myostatin inhibition removes a ceiling that isn't being actively pushed against.

How is Follistatin dosed?

No human trial has established a subcutaneous injectable-peptide dose for follistatin. The figures below are split into what the cited literature administered and, separately, community-reported practice.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

Human trial (gene therapy, Becker muscular dystrophy). Mendell et al. (Mol Ther, 2015, PMID 25322757) delivered AAV1.CMV.FS344 — a gene-therapy vector, not the injectable FS-344 protein — by a single bilateral intramuscular quadriceps injection to six patients. Cohort 1 (n=3) received 3×1011 vector genomes/kg/leg; Cohort 2 (n=3) received 6×1011 vg/kg/leg. This is a Phase 1/2a human trial, but the dose is a one-time gene-therapy vector quantity, not a repeatable mcg/day figure, and it establishes nothing about injectable-peptide dosing. The trial reported no adverse effects and functional improvement (6-minute walk test) in most patients, more pronounced at the higher dose.

Human observational (adverse-event case series). Dağ et al. (Int Ophthalmol, 2020, PMID 32671599) is a retrospective case series of 11 bodybuilding athletes who developed central serous chorioretinopathy (CSCR, a retinal fluid condition causing vision changes) after injecting complete 1 mg vials of follistatin-344 subcutaneously in the abdomen — a single high-dose injection in eight patients, repeated high-dose injections in three. Subretinal fluid resolved over roughly 2.3 months on average after a single injection; three patients with repeated high-dose use had recurrent CSCR. This is Human Observational evidence (a case series, not a controlled trial) but it is the only published human data specifically on subcutaneous injectable FS-344 use, and it documents the 1 mg dose as the one actually observed in affected patients, not merely a theoretical ceiling.

Community-reported practice (unverified)

Reported research-community practice — attributed to where it circulates, not to either study above, and not independently verified by Prof. Peptide — is 100–200 mcg subcutaneously per day (100 mcg for an initial cycle), for 10–30 days on with 3–4 weeks off. This diverges from the cited case series in dose magnitude: the community figure is roughly 5–10× lower than the complete 1 mg vials the CSCR patients injected, and the community convention of staying at or below 200 mcg/day appears to be, in part, a response to those adverse-event reports rather than an independently derived figure. No source was found establishing 100–200 mcg/day as safe or effective; it is simply the amount reported to circulate below the dose observed to cause CSCR.

Cycle structure rationale: follistatin cycling is designed to allow the body to re-establish baseline myostatin levels and any reproductive hormone changes to normalize. Some users do shorter, more frequent pulses (e.g., 10 days on, 3 weeks off, repeated) for sustained effect with reduced reproductive impact. Most experienced users keep cycles short — 10–14 days — and stack with longer-cycle compounds rather than running follistatin alone for extended periods.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

How is Follistatin administered?

Follistatin is given as a subcutaneous injection — under the skin, not into muscle — daily during the cycle, using a small insulin syringe. Reconstitution technique matters more for follistatin than for most peptides: FS-344 is a 344-amino-acid fragile glycoprotein that denatures with rough handling. For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection, daily during the cycle. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Time of day. Any time, but consistent. Many users inject in the morning or post-workout to align peak levels with training stimulus.
  3. With or without food. Either is fine.
  4. Site rotation. Rotating sites each day, with at least an inch between consecutive sites, is the convention for limiting localized irritation.
  5. Missed dose. Reported practice skips and resumes the next day. The convention is not to double-dose — the short half-life means a doubled dose would briefly spike well above the recommended ceiling without sustained benefit.
  6. Reconstitution handling. Bacteriostatic water is reported added slowly down the inside wall of the vial — not sprayed directly onto the powder — with a gentle swirl or roll until dissolved rather than shaking, which denatures the peptide. Follistatin is a large glycoprotein and denatures with rough handling.
  7. Cycle structure. 10–30 days on, 3–4 weeks off. Continuous use has not been studied.

Timing context. Follistatin is administered daily via subcutaneous injection during the cycle. Unlike long-acting GLP-class peptides, follistatin's ~90-minute half-life means each injection's effect window is short — daily consistency matters more than precise time of day. The two timing variables that matter most are cycle structure (10–30 days on, 3–4 weeks off) and pairing with training (many users inject pre- or post-workout to align peak levels with the training stimulus).

AspectReported
FrequencyDaily; a 10–30 days on, 3–4 weeks off cycle is reported community practice, not derived from a trial or label; Prof. Peptide has not independently verified it.
Best time of dayAny consistent time — many users inject pre- or post-workout
FoodNo fasting required; inject with or without food
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to Follistatin.
Half-life~90 minutes (1.5 hours)
Steady-stateFunctional steady-state reached within ~3 days at consistent daily dosing

Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. Follistatin research vials are typically 1 mg. Because Follistatin doses are small (50–200 mcg daily during cycles), 2 mL reconstitution is the common research convention — it gives clean whole-number units across the dose range and uses gentle dilution that respects the protein's fragility. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 1 mg vial.

BAC waterConcentration50 mcg dose100 mcg dose150 mcg dose200 mcg dose
1 mL1 mg/mL5 units10 units15 units20 units
2 mL0.5 mg/mL10 units20 units30 units40 units
3 mL0.33 mg/mL15 units30 units45 units60 units

Units vs mcg. At a 1 mg vial, each unit drawn delivers 10 mcg of Follistatin at 1 mL reconstitution, 5 mcg at 2 mL, and 3.3 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does Follistatin stack well with?

Follistatin pairs naturally with anabolic and recovery peptides because it removes the myostatin growth ceiling without directly providing growth signal. The cleanest additions are IGF-1 LR3 (for direct growth signal through IGF-1 receptors) and GH secretagogues (for systemic GH/IGF-1 elevation). The recovery peptides (BPC-157, TB-500) are added during anabolic cycles to support connective tissue under heavier loads. The things to avoid are other myostatin-pathway compounds — redundant mechanism, no proportional benefit.

  1. IGF-1 LR3. Direct synergy. Follistatin removes the myostatin growth ceiling; IGF-1 LR3 amplifies the growth signal. The most mechanistically complementary stack for advanced muscle-building research.
  2. GH secretagogues. GH Stack (CJC-1295 + Ipamorelin) or MK-677 are combined for systemic growth hormone elevation alongside myostatin inhibition. Different pathways, additive effects.
  3. Recovery peptides during anabolic cycles. Wolverine Stack (BPC-157 + TB-500) accelerates tissue repair while follistatin removes growth limits — useful when heavier training loads put more strain on tendons and joints.
  4. Resistance training + 1.6–2.2 g/kg protein. Essential. Without training stimulus and sufficient protein, follistatin's effects are minimal — the myostatin ceiling is only worth removing if growth is being actively driven.
  5. Conflicts: multiple myostatin-pathway compounds. Stacking with other myostatin-targeting compounds (ACE-031, YK11) is redundant mechanism with increased side-effect risk and no proportional benefit.

What are the side effects of Follistatin?

Follistatin's side-effect profile is the most uncertain among muscle-building peptides because controlled injectable-peptide human data is minimal, though a published case series documents central serous chorioretinopathy in bodybuilders who injected complete 1 mg vials. Gene therapy approaches have shown clean safety profiles in primates and Becker muscular dystrophy patients, but those results don't translate directly to injectable peptide use. The main concerns are reproductive hormone modulation (via activin binding) and the documented retinal-fluid effect at 1 mg doses. Cycling on/off is essential, not optional.

Common (most users)

  1. Injection site reactions. Mild redness or irritation at the injection site, especially with daily dosing.
  2. Headache or fatigue. Reported during cycles, typically mild.
  3. Mild flu-like symptoms. Uncommon but reported, usually in the first few days of a cycle.

Less common (moderate)

  1. Reproductive hormone changes. Follistatin binds activin, which regulates FSH. Changes in FSH and downstream reproductive hormones can occur during use — typically transient and resolve after cycling off.
  2. Joint pain or stiffness. Reported during anabolic cycles, often related to rapid strength gains outpacing connective tissue adaptation.
  3. Mild bloating or fluid retention. Inconsistent across users.

Serious (rare)

  1. Central serous chorioretinopathy (Dağ et al., Int Ophthalmol, 2020, PMID 32671599). Vision changes from retinal fluid — documented in a retrospective case series of 11 bodybuilders who injected complete 1 mg vials subcutaneously (roughly 5–10× the community-reported 100–200 mcg/day figure); symptoms resolved over an average of 2.3 months after a single injection, but recurred in patients with repeated high-dose use.
  2. Theoretical fertility effects. Sustained activin pathway modulation could affect long-term reproductive function. Reproductive hormones are what reported protocols monitor where fertility is a concern.
  3. Theoretical tumor-growth acceleration. Satellite-cell and growth-pathway activation could accelerate pre-existing tumors, so any history of malignancy is treated as a theoretical exclusion in research contexts.

Follistatin's safety profile is the most uncertain among muscle-building peptides because injectable peptide human data is minimal. Gene therapy approaches have shown clean safety profiles in primates and Becker muscular dystrophy patients, but those results don't directly translate to injectable peptide use. Reproductive considerations are real — monitor reproductive hormones if fertility is a concern. Cycling on/off is essential, not optional.

Does Follistatin interact with other drugs?

Follistatin's most relevant interactions are with reproductive hormone medications (via its activin/FSH effect), other myostatin-pathway compounds (redundant mechanism), and anabolic-androgenic steroids (theoretical synergy with compounding side-effect risk). No major drug-drug pharmacokinetic interactions have been reported in published research.

  1. Reproductive hormone medications. Follistatin's activin binding affects FSH regulation. Theoretical interaction with fertility treatments, hormonal contraceptives, or testosterone-related medications.
  2. Other myostatin pathway compounds (ACE-031, YK11). Combination is redundant mechanism with increased side-effect risk; not recommended.
  3. Anabolic-androgenic steroids. Theoretical synergy via different mechanisms; combination increases overall side-effect risk including joint/connective-tissue strain from compounded growth signaling.
  4. No major drug-drug pharmacokinetic interactions reported in published research.

How should Follistatin be stored?

  1. Lyophilized (powder) form: Store at -20°C for long-term storage; 2–8°C acceptable for short-term.
  2. Reconstituted solution: refrigeration at 2–8°C is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade follistatin remains stable — fragile glycoproteins are widely reported to be less stable once reconstituted than smaller peptides generally, but this page does not state a specific duration as fact.
  3. Bacteriostatic water for injection (BAC water) is reported added slowly down the inside wall of the vial, with a gentle swirl rather than shaking.
  4. The reconstituted solution is never frozen.
  5. Follistatin is stored protected from light, in the original carton.
  6. A solution that is cloudy, discolored, or contains particles is discarded. Follistatin is more prone to denaturation than smaller peptides.

What are the limitations of Follistatin research?

Follistatin (FS-344) injectable peptide is not FDA-approved for any human use. The strongest clinical evidence comes from AAV1-FS344 gene therapy trials in Becker muscular dystrophy, not injectable peptide use. Most injectable peptide use sits outside published research, and the World Anti-Doping Agency added follistatin to the prohibited list in 2019. Counterfeit product is common — verify Certificate of Analysis before purchase.

Follistatin (FS-344) injectable peptide is not FDA-approved for any human use. The strongest clinical evidence for follistatin comes from AAV1-FS344 gene therapy trials in Becker muscular dystrophy, not injectable peptide use. Gene therapy provides sustained expression for months from a single dose; injectable peptide has a 90-minute half-life requiring daily injection.

Most injectable peptide use sits outside published research. Effects on muscle in humans from subcutaneous injection are not formally validated through controlled trials. Doses, cycles, and outcomes are derived from research community practice rather than clinical evidence.

The World Anti-Doping Agency added follistatin to the prohibited list in 2019 under Section S2 (peptide hormones). It is subject to doping detection methods.

Counterfeit follistatin is common in the gray market. Recombinant production is expensive — extremely cheap product is suspect. Certificate of Analysis verification is critical.

Research-grade material is sold for laboratory use only and is not approved for human consumption.

Follistatin FAQ

What's the difference between FS-344, FS-315, and FS-288?

FS-344 is the 344-amino-acid precursor protein that's the standard injectable form. After injection, it's cleaved in vivo into FS-315 (the 315-amino-acid circulating isoform that targets muscle and binds myostatin systemically) and FS-288 (the 288-amino-acid tissue-bound isoform that concentrates in reproductive tissue and binds activin). Injecting FS-344 produces both — you can't get pure myostatin inhibition without some activin/reproductive effect.

Does the injectable peptide work as well as gene therapy?

Almost certainly not. Gene therapy with AAV1-FS344 produces sustained follistatin expression for 15+ months from a single dose, generating dramatic muscle growth (15% circumference in primates, improved ambulation in BMD patients). Injectable FS-344 has a 90-minute half-life and clears rapidly, so effects are far more modest. Injectable peptide effects are sometimes reported in 2–4 week pulses combined with training, though no trial or label has been identified establishing this timeframe.

Will follistatin affect my fertility?

Possibly. Follistatin binds activin, which regulates FSH (follicle-stimulating hormone). Activin pathway modulation can affect reproductive hormones during use. Most reported effects are transient and resolve after cycling off. If fertility is an active concern, monitor reproductive hormones during cycles or consider alternative compounds. The FS-288 isoform (which concentrates in gonads) is the source of most reproductive effect.

Why is follistatin so expensive?

Follistatin is a 344-amino-acid glycoprotein, one of the largest research peptides. It requires recombinant expression in mammalian or yeast systems rather than standard solid-phase peptide synthesis. The production complexity drives cost — extremely cheap product is suspect for purity or content.

How long are typical cycles?

10–30 days on, 3–4 weeks off (off-period 2–3x the cycle length). Most experienced users run shorter cycles — 10–14 days — to limit reproductive hormone effects and rotate through other compounds. Continuous use has not been studied.

Is follistatin the same as myostatin inhibitors like ACE-031 or YK11?

Different mechanisms in the same general direction. Follistatin is the natural endogenous myostatin inhibitor — it binds and neutralizes myostatin directly. ACE-031 (a soluble decoy receptor) and YK11 (a SARM) target the myostatin pathway through different mechanisms with different side effect profiles. Follistatin has the most direct mechanism but the most uncertain injectable peptide human data.

Can follistatin be stacked with IGF-1 LR3?

Yes — this is one of the most mechanistically complementary stacks. Follistatin removes the myostatin growth ceiling; IGF-1 LR3 amplifies the growth signal directly through IGF-1 receptors. Some users combine both with GH secretagogues for an aggressive anabolic protocol. Side effects compound — careful cycling and dose titration are essential.

Where can I buy follistatin?

Follistatin is sold by specialty research peptide vendors. Counterfeit and underdosed product is common — verify Certificate of Analysis before purchase. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Rodino-Klapac LR, Haidet AM, Kota J, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009;39(3):283-96. https://pmc.ncbi.nlm.nih.gov/articles/PMC2717722/
  2. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-β signaling pathways. PLoS One. 2007;2(8):e789. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000789
  3. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23(1):192-201. https://pubmed.ncbi.nlm.nih.gov/25322757/
  4. Iezzi S, Di Padova M, Serra C, et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell. 2004;6(5):673-84. https://pubmed.ncbi.nlm.nih.gov/15130492/
  5. Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2852878/
  6. Datta-Mannan A, Yaden B, Krishnan V, et al. An engineered human follistatin variant: insights into the pharmacokinetic and pharmacodynamic relationships of a novel molecule with broad therapeutic potential. J Pharmacol Exp Ther. 2013;344(3):616-23. Addendum: J Pharmacol Exp Ther 2015, PMID 26188066. https://pubmed.ncbi.nlm.nih.gov/23249626/
  7. Dağ U, Çağlayan M, Öncül H, Alakuş MF. Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. Int Ophthalmol. 2020;40(11):3155-3161. https://pubmed.ncbi.nlm.nih.gov/32671599/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Developmental Biology / PubMed · 2004Abstract open
Follistatin Complexes Myostatin and Antagonises Myostatin-Mediated Inhibition of Myogenesis →

Amthor H, et al.

The foundational study establishing the direct molecular interaction between follistatin and myostatin — the key biological relationship that makes follistatin relevant to muscle growth research. The researchers demonstrated that follistatin binds myostatin with extremely high affinity and physically blocks it from executing its muscle-suppressing function. When chick limb buds were treated with myostatin alone, expression of the myogenic genes Pax-3 and MyoD was severely reduced — but when follistatin was added alongside myostatin, this inhibition was completely blocked. This established follistatin as myostatin’s natural antagonist and the scientific foundation for all subsequent FS344 research.

Proceedings of the National Academy of Sciences (PNAS) / PMC · 2008Open Access
Long-Term Enhancement of Skeletal Muscle Mass and Strength by Single Gene Administration of Myostatin Inhibitors →

Haidet AM, Rizo L, Handy C, et al.

A landmark study showing that a single intramuscular injection of AAV1-FS344 produced sustained increases in muscle mass and strength for over two years in both normal and dystrophic mice — including when treatment was started in aged animals. FS344 outperformed other myostatin inhibitors (GASP-1, FLRG) in terms of both muscle size and functional strength improvement. Crucially the study found no adverse effects on cardiac pathology or reproductive capacity in male or female treated animals — directly addressing the primary safety concern (FSH suppression) that had limited earlier follistatin research. This paper was the foundation for the first human clinical trial.

Muscle & Nerve / PMC · 2009Open Access
Inhibition of Myostatin with Emphasis on Follistatin as a Therapy for Muscle Disease →

Rodino-Klapac LR, Haidet AM, Kota J, et al.

A comprehensive review establishing the scientific rationale for FS344 as a muscle disease therapeutic. The paper explains why the FS344 isoform specifically was selected for clinical development — its 10-fold lower affinity for activin compared to FS288 means it is far less likely to suppress FSH and interfere with reproductive function, the primary safety concern with follistatin. The review documents that AAV1-FS344 produced grip strength improvements in treated mice for over two years, and that muscle mass was increased across all treated animals. This paper set the stage for the first human clinical trial.

American Journal of Physiology — Endocrinology and Metabolism · 2009Open Access
Follistatin Induces Muscle Hypertrophy Through Satellite Cell Proliferation and Inhibition of Both Myostatin and Activin →

Gilson H, Schakman O, Kalista S, et al.

This study revealed that follistatin’s muscle-building effects operate through two distinct mechanisms — myostatin inhibition AND activin inhibition — and that satellite cells (muscle stem cells) play a critical role. FS overexpression increased muscle weight by 37% in normal animals but only 20% in irradiated animals (which lacked functional satellite cells), confirming that satellite cell proliferation drives a significant portion of the hypertrophic effect. Strikingly, FS produced equal muscle hypertrophy in both normal mice AND myostatin knockout mice — proving that follistatin’s muscle growth effects extend well beyond simply blocking myostatin, implicating activin and other TGF-β family members as additional targets.

Journal of Neuromuscular Diseases / PMC · 2015Open Access
Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy →

Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, et al.

The first human clinical trial of follistatin gene therapy — a landmark study delivering FS344 via intramuscular injection to patients with Becker muscular dystrophy. Six patients received bilateral quadriceps injections and were followed for safety and efficacy. The trial demonstrated that FS344 gene delivery was safe and well tolerated in humans, with no adverse reproductive effects or organ toxicity. Functional improvements in ambulation (walking ability) were observed in treated patients. This study represents the bridge between decades of animal research and human clinical application of follistatin — establishing its safety profile in humans for the first time.

Muscle GrowthMyostatin InhibitorAnabolicResearch-Grade

Related Peptides

IGF-1 LR3CJC-1295IpamorelinMK-677BPC-157TB-500

Related Blends

GH StackWolverine Stack

We may earn commissions from peptide vendor affiliate links.

Have a question about Follistatin? Send us an email